Overview

NIvolumab COmbination With Standard First-line Chemotherapy and Radiotherapy in Locally Advanced Stage IIIA/B Non-Small Cell Lung Carcinoma

Status:
Completed

Trial end date:
2020-03-31

Target enrollment:

Participant gender:

Summary

The aim of the study is to investigate the tolerability (how severe the side effects are) and the efficacy (how well the treatment works) when nivolumab is added to the current standard treatment (chemotherapy and radiotherapy) given to patients with advanced NSCLC.

Phase:

Phase 2

Details

Lead Sponsor:

European Thoracic Oncology Platform

Collaborators:

Bristol-Myers Squibb
Frontier Science Foundation, Hellas

Treatments:

Antibodies, Monoclonal
Nivolumab